Person:
BALABAN ADIM, ŞADUMAN

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

BALABAN ADIM

First Name

ŞADUMAN

Name

Search Results

Now showing 1 - 10 of 21
  • Publication
    A comparative study of cd56 and smooth muscle actin expression in basal and squamous cell carcinomas
    (Lippincott Williams & Wilkins, 2023-12-01) Yirmibeş, Selin; Balaban Adım, Saduman; BALABAN ADIM, ŞADUMAN; Tıp Fakültesi; Patoloji Ana Bilim Dalı
    Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the 2 most common types of nonmelanoma skin tumors. Clinical or histopathological diagnostic challenges are encountered on occasion. CD56 and smooth muscle actin (SMA) are highly expressed in BCCs. We aimed to investigate the frequency of these markers, along with B-cell lymphoma 2 (Bcl-2) and Ki67. This study was conducted to propose a method that could possibly be of diagnostic value. One hundred twenty-eight BCC and 39 SCC cases were included in this study. CD56, SMA, Bcl-2, and Ki67 immunohistochemical stains were applied. Ninety-nine (77.3%) BCC and 6 (15.4%) SCC cases showed CD56 immunoreactivity. SMA expression was detected in 78.1% of BCC and 5.1% of SCC cases. CD56, SMA, and Bcl-2 expressions were significantly higher in BCC cases. The Ki67 proliferation index was found significantly higher in SCC cases. When basosquamous carcinoma cases were compared with SCC cases, a significant correlation between tumors and expression of CD56, SMA, and Bcl-2 were obtained. CD56 and SMA, in addition to Bcl-2, favor BCC. Ki67 should also be included in the panel to demonstrate the proliferative activity.
  • Publication
    Birt-hogg-dube syndrome: Diagnostic journey of three cases from skin to gene
    (Korean Dermatological Assoc, 2022-02-01) Gül, Şeref; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Temel, Şehime Gülsün; TEMEL, ŞEHİME GÜLSÜN; Hasal, Eda; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Sag, Şebnem Özemri; ÖZEMRİ SAĞ, ŞEBNEM; Adım, Şaduman Balaban; BALABAN ADIM, ŞADUMAN; Tıp Fakültesi; Tıbbi Genetik Ana Bilim Dalı; 0000-0001-6310-5107; 0000-0001-7099-9647; 0000-0002-9802-0880; AAG-8385-2021; AAH-8355-2021
    Birt-Hogg-Dube syndrome (BHDS) is a rare disorder characterized by the triad of cutaneous lesions, renal tumors, lung cysts and inactivation of the gene folliculin (FLCN). Here, we present three female patients diagnosed with BHDS. First case a 55-year-old female had flesh moles histopathology compatible with angiofibroma, multiple cysts in the lung and kidneys, FLCN gene mutations ('c.1285dupC [p.His429Profs*]' 11th exon and 'c.653G>A [p.Arg258His]' 7th exon). The second case a 76-year-old female had trichodiscoma on her skin, multiple cysts in the lung, spontaneous pneumothorax, FLCN gene mutation 'c.1285dupC (p.His429Profs*27) 11th exon' and, her son had renal carcinoma history under 50 years of age. Our third case, also the daughter of case 2, had dermal papules histopathology compatible with trichodiscoma, spontaneous pneumothorax, FLCN gene mutation 'c.1285dupC (p.His429Profs*27) 11th exon' and, parotid oncocytoma. Through our cases, we document the first case of two mutations ('c.1285dupC [p.His429Profs*]' 11th exon and 'c.653G>A [p.Arg258His]' 7th exon) in the same FLCN gene and the 11th known case of parotid oncocytoma associated with BHDS in the light of the literature.
  • Publication
    Cd56 and smooth muscle actin immunoreactivity in basal cell carcinomas: Are they indicators of differentiation or do they hold a diagnostic use?
    (Wiley, 2022-09-21) Yirmibeş, Selin; Adım, Şaduman Balaban; BALABAN ADIM, ŞADUMAN; Saraydaroğlu, Özlem; SARAYDAROĞLU, ÖZLEM; Tıp Fakültesi; Patoloji Ana Bilim Dalı
    Background Basal cell carcinoma (BCC) is the most common cutaneous malignancy and may show various differentiations. The possible pluripotent stem cell lineage of BCCs, whose origins are controversial today, is thought to be the main reason for the different morphologies. The aim of the study is to evaluate the expression of some neuroendocrine and smooth muscle markers of differentiation in BCCs and investigate the relationship between histopathologic subtypes and recurrence. Methods A total of 128 cases diagnosed as BCC in our center were included. Immunohistochemical studies of CD56, synaptophysin, chromogranin-A, smooth muscle actin (SMA), desmin, caldesmon, and Ki67 were applied. Results CD56, chromogranin-A, and synaptophysin immunoreactivity were detected in 77.3%, 13.3%, and 0.8% of the cases, respectively. 78.1% showed SMA positivity while no tumor expressed desmin or caldesmon. A correlation between histopathologic recurrence risk groups and CD56 expression was found (p < 0.05). Conclusions CD56 and SMA immunoreactivity is present in the majority of BCCs. However, the available findings do not support neuroendocrine or smooth muscle differentiation. CD56 antigen can be used for prognostic purposes in detecting high recurrence risk tumors. After the investigation of the expression rates of these two antigens in different cutaneous tumors, it may be appropriate to use them for diagnostic purposes in BCCs.
  • Publication
    Effects of Taxol plus radiation on the apoptotic and mitotic indices of mouse intestinal crypt cells
    (Springer, 2001-07-01) Özkan, L; Özuysal, S; Egeli, Ü; Adım, Şadan Balaban; Tunca, Berrin; Aydemir, N; Çeçener, G; Ergül, E; Akpınar, G; Çimen, Ç; Engin, K; Ahmed, M. M; Özkan, L; Özuysal, S; EGELİ, ÜNAL; BALABAN ADIM, ŞADUMAN; TUNCA, BERRİN; Aydemir, N; Çeçener, G; Ergül, E; Akpınar, G; Çimen, Ç; Engin, K; Ahmed, M. M; Tıp Fakültesi; Radyasyon Onkolojisi Ana Bilim Dalı; 0000-0002-1619-6680; 0000-0002-3595-6286; 0000-0002-3820-424X; 0000-0002-9675-3714; F-9745-2018; ABI-6078-2020; AAP-9988-2020; F-7337-2018; AAH-5296-2021; AAK-5988-2020; JKS-6264-2023; DJS-2456-2022; EMN-0789-2022; AAH-5296-2021; EUB-7112-2022; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı
    Purpose: In this study we investigated the effect of Taxol, radiation, or Taxol plus radiation on highly proliferative normal tissue - the intestinal crypt cells of Swiss albino mice. Materials and methods: Swiss-albino mice, 3-4 months old, were used in this study. Taxol was administered by bolus intravenously through the tail vein. Radiation was given using a linear accelerator. There were four treatment categories, which comprised a total of 34 groups. Each group consisted of five animals. The first category was a control category which comprised one group (n = 5). The second treatment category was Taxol alone which comprised three groups (n = 15). The third treatment category was radiation alone which comprised three groups (n = 15). The fourth treatment category was Taxol plus radiation which comprised 27 groups (n = 135). Mice were killed 24 h after Taxol or radiation or combined administration using ether anesthesia. Using a light microscope, apoptotic and mitotic indices were counted on jejunal crypt cells of mice that were stained with hematoxylin-eosin. Differences between groups were statistically evaluated with Student's t-test. Results: Taxol caused a dose-dependent increase in apoptosis (P = 0.045) and decreased the mitotic index (P = 0.006) at high doses. Similarly, radiation caused a dose-dependent increase in apoptosis (P = 0.046) and decreased the mitotic index (P = 0.299) at higher radiation doses. Compared to radiation alone, Taxol caused a significant induction of apoptosis (P = 0.010). In combination, no significant radiosensitizing effect of Taxol was observed (enhancement ratio < 1), when compared to radiation alone. However, an increase in apoptosis was observed after 24 h of Taxol exposure when compared to 12 or 48 h of Taxol exposure (P = 0.0001 and P = 0.0001). Conclusion: These findings suggest that Taxol did not cause a radiosensitizing effect in intestinal crypt cells. However, a 24-hour pretreatment of Taxol exposure followed by radiation caused significant induction of apoptosis and reduction of the mitotic index when compared to other Taxol timing sequences. Thus, the lack of a radiosensitizing effect of Taxol in these proliferative cells may be due to enhanced mitotic death rather than apoptotic death.
  • Publication
    A report of 13 cases of merkel cell carcinoma: Single-center experience and review of the literature
    (Korean Dermatological Assoc, 2019-06-01) Yazıcı, Serkan; Yazıcı, Elif Irmak; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Aydoğan, Kenan; Sarıcaoğlu, Hayriye; YAZİCİ, SERKAN; Yazıcı, Elif Irmak; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; AYDOĞAN, KENAN; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-2459-2021; AAH-6216-2021; IHQ-3086-2023; EMN-0789-2022; DPU-8534-2022
    Background: There is limited data knowledge of Merkel cell carcinoma (MCC) in Turkey aside from a few case reports. Objective: The aim of this study was to describe the clinical characteristics, demographic features, therapeutic parameters, and outcome of primary cutaneous MCC cases from Turkey. Methods: Digital medical records of the 13 MCC patients who were followed-up at a tertiary referral center were retrospectively analyzed. Clinic, demographic, tumor characteristics, and survival of the patients were retrieved. Results: Most of our patients were elderly. Female predominance was noticed. The most common primary site of the tumors was the lower extremities. The overall survival was 42 months, 68% at first year, 68% at third years, and 29% at fifth years. Conclusion: This is the first largest report from Turkish population with female predominance, and lower extremity tendency.
  • Publication
    Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study
    (Deri Zuhrevi Hastaliklar Dernegi, 2015-01-01) Kaçar, Seval Dogruk; Kaçar, Emre; Baskan, Emel Bulbul; BÜLBÜL BAŞKAN, EMEL; Bolca, Naile; BOLCA TOPAL, NAİLE; Adım, Sadiman Balaban; BALABAN ADIM, ŞADUMAN; Tunalı, Şükran; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Radyoloji Ana Bilim Dalı; JLM-2426-2023; AAH-1388-2021
    Background and Design: Despite the development of effective systemic treatments and new biological agents for psoriasis nowadays, topical medications are still the mainstay of treatment. Topical calcineurin inhibitors are currently used in various skin diseases. We investigated the efficacy and safety of tacrolimus, which is an alternative in topical treatment, in comparison with the present medications in plaque psoriasis.Materials and Methods: This prospective double-blind placebo-controlled study was conducted in 24 patients with the diagnosis of plaque psoriasis who were seen in Uludag University Hospital dermatology outpatient clinic. 0.1% tacrolimus ointment, 0.1% mometasone furoate ointment, 0.005% calcipotriol ointment and placebo in encrypted bottles were randomly applied under occlusion to 27 psoriatic plaques in test chambers, every other day, for a period of 19 days. Clinic sum scores, side effects, and epidermal thickness measured by superficial ultrasound were noted before and after treatment in all microplaques. Besides, histopathologic scoring and epidermal thickness were measured in 9 patients at the end of the study.Results: The clinic sum scores and ultrasonographic epidermal thickness at the end were both significantly lower than the beginning values in all microplaques (p<0.05). The reduction in these two values with tacrolimus were significantly higher than that with placebo (p<0.001), but no difference was observed with calcipotriol (p=0.287, p=0.813, respectively). On the other hand, the reduction in these values with mometasone was significantly higher than with tacrolimus (p<0.05). Mometasone furoate was the most effective when the three ointments were compared with placebo in terms of total histopathological score and epidermal thickness.Conclusion: Tacrolimus ointment applied under occlusion is an alternative topical medication in the treatment of plaque psoriasis. Occlusion in practice requires patient compliance. Thus, studies to find a new formulation that will increase absorption of drug from thick psoriatic plaques are needed.
  • Publication
    The effects of topical prophylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study
    (Türk Sosyoloji Dermatoloji Veneroloji, 2005-01-01) Toker, Semra Çıkman; Sarıcaoğlu, Hayriye; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Karadoğan, Serap Koran; Tunalı, Şükran; Toker, Semra Çıkman; SARICAOĞLU, HAYRİYE; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; Karadoğan, Serap Koran; Tunalı, Şükran; Tıp Fakültesi; Patoloji Ana Bilim Dalı; AAH-1388-2021; AAH-6216-2021; CBU-2730-2022; DPU-8534-2022; EMN-0789-2022; GGH-7385-2022
    Background and Design: Propylthiouracil (PTU) decreases the synthesis of thyroid hormon as well as having immune modulatory and free radical scavenging effects. Oral PTU has been shown to be effective for the treatment of plaque psoriasis in several studies. This study was performed to determine the efficacy of topical PTU in psoriasis.Materials and Methods: Different plaques of 16 patients with plaque psoriasis were treated with 5% topical PTU and placebo, three times daily for 8 weeks in a setting of a double-blind and placebo controlled study. Response to therapy was evaluated by using clinical score, histopathologic score and epidermal thickness.Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p<0.001). The epidermal thickness of the psoriatic PTU plaques before and after treatment were 0.57 +/- 0.1 mm and 0.46 +/- 0.19 mm, respectively. Furthermore, no significant difference was observed between the pre- and post-treatment histopathological findings of plaques treated with PTU.Conclusion: Topical PTU may be viable steroid-sparing agent, since topical corticosteroid as a conventional agent, have many side effects. Since we didn't observe a significant difference between the plaques treated with PTU and placebo in our group, we concluded that further studies with larger series should be performed to confirm this hypothesis.
  • Publication
    Lupus miliaris disseminatus faciei: A case report
    (Wolters Kluwer Medknow Publications, 2013-06-01) Başkan, Emel Bülbül; Turan, Ayşegül; Turan, Hakan; Adım, Şaduman Balaban; Şarıcaoğlu, Hayriye; BÜLBÜL BAŞKAN, EMEL; BALABAN ADIM, ŞADUMAN; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Dermatoloji Ana Bilim Dalı; AAH-1388-2021; EMN-0789-2022; DPU-8534-2022
    Lupus miliaris disseminatus faciei (LMDF) is a chronic, rare inflammatory dermatosis characterized by yellowish-red papules with a smooth surface especially on the face and around the eyelids. Recently, due to its histological appearance and different involvement areas, the predominated idea is that it is a granulomatous reaction against to the hair follicle destruction and ruptured epidermoid cysts. A 32-year-old female patient admitted to our outpatient clinic because of the acne lesions on her face and hands for 2 months. The patient was diagnosed as LMDF with clinical and histopathologic findings. In addition, biopsy of the papules around the eyelids revealed epidermoid cyst structures associated with the granulomas. On the occasion of this case, we revised LMDF, a dermatosis which still causes different ideas about naming and etiopathogenesis, in the light of the literature; we discussed differential diagnosis and we analyzed the association with epidermoid cysts.
  • Publication
    Response to Comment: A challenging case: Multiple and Blaschkoid hair follicle naevi or supernumerary accessory tragi? (Saricaoglu et al., 2019)
    (Wiley, 2019-09-01) Zorlu, Özge; Adım, Şaduman Balaban; Sarıcaoğlu, Hayriye; Demirkesen, Cuyan; Zorlu, Özge; BALABAN ADIM, ŞADUMAN; SARICAOĞLU, HAYRİYE; Demirkesen, Cuyan; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-5555-130X; ABD-1191-2021; EMN-0789-2022; DPU-8534-2022; CLY-8411-2022
  • Publication
    Tuberculosis of the sclera
    (Turkish Ophthalmological Soc, 2008-07-01) Eser, İlker; UÇAN GÜNDÜZ, GAMZE; Uçan, Gamze; Yazıcı, Bulent; Adım, Saduman Balaban; BALABAN ADIM, ŞADUMAN; Tıp Fakültesi; Patoloji Ana Bilim Dalı; 0000-0002-5458-1686; 0000-0001-8889-1933; AAA-5384-2020; AAH-6661-2021
    A 53-year-old female patient who presented with an inflamated scleral mass was diagnosed as scleral tuberculosis as a result of histopathologic evaluation. Systemic evaluation showed no evidence of tuberculosis. The patient received a multi-drug anti-tuberculosis treatment for 9 months. After treatment, all ocular symptoms improved and no recurrence occurred in the 22 months following the treatment. Scleral tuberculoma should be considered in patients presented with an inflammated mass in the sclera. In some cases, histopathological findings and positive response to the medical treatment may be sufficient for the diagnosis.